Comparative Pharmacology
Head-to-head clinical analysis: GLOFIL 125 versus NEPHROSCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLOFIL 125 versus NEPHROSCAN.
GLOFIL-125 vs NEPHROSCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GLOFIL-125 (pentoxifylline) is a xanthine derivative that improves erythrocyte flexibility by inhibiting phosphodiesterase, leading to increased intracellular cAMP. It also reduces blood viscosity and platelet aggregation, improving microcirculation.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
125 mg orally twice daily.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
None Documented
None Documented
Terminal elimination half-life: 2.5–3.5 hours (prolonged in renal impairment; up to 20–30 hours in severe chronic kidney disease).
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug >90%; biliary/fecal <5%.
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical